Welcome to LookChem.com Sign In|Join Free

CAS

  • or

99409-34-4

Post Buying Request

99409-34-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

99409-34-4 Usage

General Description

Ethyl 2,3,4-tri-O-benzyl-1-thio-beta-L-fucopyranoside is a chemical compound with the molecular formula C31H32O5S. It is a fucosyl donor used in glycosylation reactions to modify carbohydrates and create complex oligosaccharides. ETHYL 2,3,4-TRI-O-BENZYL-1-THIO-BETA-L-FUCOPYRANOSIDE is derived from fucose, a naturally occurring sugar found in many biological systems. Its benzyl-protected thiol functionality makes it a useful reagent for organic synthesis and carbohydrate chemistry.ETHYL 2,3,4-TRI-O-BENZYL-1-THIO-BETA-L-FUCOPYRANOSIDE is a potentially useful chemical compound with applications in various fields of research and chemical synthesis.

Check Digit Verification of cas no

The CAS Registry Mumber 99409-34-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,9,4,0 and 9 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 99409-34:
(7*9)+(6*9)+(5*4)+(4*0)+(3*9)+(2*3)+(1*4)=174
174 % 10 = 4
So 99409-34-4 is a valid CAS Registry Number.
InChI:InChI=1/C29H34O4S/c1-3-34-29-28(32-21-25-17-11-6-12-18-25)27(31-20-24-15-9-5-10-16-24)26(22(2)33-29)30-19-23-13-7-4-8-14-23/h4-18,22,26-29H,3,19-21H2,1-2H3/t22-,26+,27+,28-,29+/m0/s1

99409-34-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name (2R,3S,4R,5R,6S)-2-ethylsulfanyl-6-methyl-3,4,5-tris(phenylmethoxy)oxane

1.2 Other means of identification

Product number -
Other names 2,3,4-Tri-O-benzyl-1-S-ethyl-|A-L-thiofucopyranoside

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:99409-34-4 SDS

99409-34-4Downstream Products

99409-34-4Relevant articles and documents

Pillar[5]arene-Based Polycationic Glyco[2]rotaxanes Designed as Pseudomonas aeruginosa Antibiofilm Agents

Coenye, Tom,De Winter, Julien,Diaconu, Andrei,Fransolet, Maude,Gillon, Emilie,Imberty, Anne,Jimmidi, Ravikumar,Michiels, Carine,Mohy El Dine, Tharwat,Vincent, Stéphane P.

supporting information, p. 14728 - 14744 (2021/10/12)

Pseudomonas aeruginosa (P.A.) is a human pathogen belonging to the top priorities for the discovery of new therapeutic solutions. Its propensity to generate biofilms strongly complicates the treatments required to cure P.A. infections. Herein, we describe the synthesis of a series of novel rotaxanes composed of a central galactosylated pillar[5]arene, a tetrafucosylated dendron, and a tetraguanidinium subunit. Besides the high affinity of the final glycorotaxanes for the two P.A. lectins LecA and LecB, potent inhibition levels of biofilm growth were evidenced, showing that their three subunits work synergistically. An antibiofilm assay using a double δlecAδlecB mutant compared to the wild type demonstrated that the antibiofilm activity of the best glycorotaxane is lectin-mediated. Such antibiofilm potency had rarely been reached in the literature. Importantly, none of the final rotaxanes was bactericidal, showing that their antibiofilm activity does not depend on bacteria killing, which is a rare feature for antibiofilm agents.

Total synthesis of LewisX using a late-stage crystalline intermediate

Munneke, Stefan,Painter, Gavin F.,Gainsford, Graeme J.,Stocker, Bridget L.,Timmer, Mattie S.M.

, p. 1 - 7 (2015/07/15)

Abstract Herein, we report on a highly efficient synthesis of a crystalline protected LewisX trisaccharide that was converted to LewisX following global deprotection. The trisaccharide was prepared in a highly convergent synthesis (seven steps, longest linear sequence) and in a 38% overall yield using a strategy that involved the regioselective glycosylation of a GlcNAc acceptor with a galactose thioglycoside donor, followed by fucosylation of the remaining free GlcNAc hydroxyl as key steps. The core trisaccharide also has the potential to be converted to other members of the Type-2 Lewis family of antigens due to the orthogonal nature of the protecting groups employed.

A new approach to explore the binding space of polysaccharide-based ligands: Selectin antagonists

Calosso, Mickael,Charpentier, Daniel,Vaillancourt, Marc,Bencheqroun, Mohammed,St-Pierre, Gabrielle,Wilkes, Brian C.,Guindon, Yvan

supporting information, p. 1045 - 1049 (2013/02/22)

The discovery of molecules that interfere with the binding of a ligand to a receptor remains a topic of great interest in medicinal chemistry. Herein, we report that a monosaccharide unit of a polysaccharide ligand can be replaced advantageously by a conformationally locked acyclic molecular entity. A cyclic component of the selectin ligand Sialyl Lewisx, GlcNAc, is replaced by an acyclic tether, tartaric esters, which link two saccharide units. The conformational bias of this acyclic tether originates from the minimization of intramolecular dipole-dipole interaction and the gauche effect. The evaluation of the binding of these derivatives to P-selectin was measured by surface plasmon resonance spectroscopy. The results obtained in our pilot study suggest that the discovery of tunable tethers could facilitate the exploration of the carbohydrate recognition domain of various receptors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 99409-34-4